In addition to affecting PD-L1 expression, KRAS mutation impacted the immunogenicity of tumour cells by downregulating the expression of major histocompatibility complex (MHC) class I molecules in a CRC cell line with the KRAS (G13D) mutation104. The gene discussed is CD274; the disease is colorectal carcinoma.